Business & Finance
PDL BioPharma reports 2018 financial results
15 March 2019 -

United States-based PDL BioPharma Inc (NASDAQ: PDLI) has reported its financial results for 12 months ended 31 December 2018.

The company reported total revenues of USD198.1m for 2018.

The firm posted a GAAP net loss of USD68.9m or USD0.47 per share for 2018.

The company repurchased 8.7 million shares of common stock in the open market during the fourth quarter of 2018 at an average price of USD2.94 per share, or USD25.5m.